Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’
The Guardian1 min read1 reads
Cancer undetectable for one in 12 patients in daraxonrasib trial, while nearly all participants’ tumours stopped growing
A year after starting treatment, 76.6% of patients were alive; usually 40-45 % of patients given chemotherapy alone survive a year. Photograph: Jeff Moore/PAA year after starting treatment, 76.6% of patients were alive; usually 40-45 % of patients given chemotherapy alone survive a year. Photograph: Jeff Moore/PAPill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’
Cancer undetectable for one in 12 patients in daraxonrasib trial, while nearly all participants’ tumours stopped growing